CD8A and neoplasm: Notably, among quantities of targeted molecules, the agents targeting ErbB augment T cell-based anti-tumor activities from multiple aspects, such as increasing the number of CD8+ T cells, enhancing cytotoxic T cell function, and reducing T cell exhaustion, especially in NSCLCs and CRCs [35].